Tag Archives: selective estrogen receptor degraders

Zentalis Leads a Trio of Biotechs Charting a Course for Wall Street

Cell therapies and antibody drugs grab much of the attention and investment in cancer drug development but the scientists at Zentalis Pharmaceuticals contend that there’s a place for small molecules too. Now the biotech is preparing for an initial public stock offering to advance its pipeline, which includes a lead candidate in testing in combination […]

Posted in Boston blog main, Boston top stories, National blog main, National top stories, New York, New York blog main, New York top stories | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Comments Off on Zentalis Leads a Trio of Biotechs Charting a Course for Wall Street

VenBio Scores Again as Genentech Pays $1.7B+ for Seragon Pharma

The big year for San Francisco, CA-based life sciences venture firm venBio just got bigger. Genentech, the big cancer drugmaker from the Bay Area, has agreed to buy a less than one-year-old San Diego, CA-based startup called Seragon Pharmaceuticals for a whopping $725 million up front. Seragon’s backers—the Column Group, OrbiMed Advisors, Aisling Capital, venBio, […]

Posted in National blog main, National top stories, San Diego, San Diego blog main, San Diego top stories, San Francisco blog main, San Francisco top stories | Tagged , , , , , , , , , , , , , , , , , | Comments Off on VenBio Scores Again as Genentech Pays $1.7B+ for Seragon Pharma